Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAMP: Pembrolizumab in Resected Merkel Cell Carcinoma
NCT03712605Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2018
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Merkel cell carcinoma (MCC) comparing Arm A (pembrolizumab, radiation therapy) with Arm B (standard of care observation, radiation therapy) (2 arms). Primary endpoints: Recurrence-Free Survival at 5 years and Overall Survival at 5 years. Started Nov 2018; status: active, not recruiting.
02
Drugs
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT03712605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03712605.